Skip to content

Effect of COP-based target lead fluid therapy on postoperative complications in patients undergoing major abdominal surgery

Effect of COP-based target lead fluid therapy on postoperative complications in patients undergoing major abdominal surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099347
Enrollment
Unknown
Registered
2025-03-21
Start date
2024-11-20
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, colorectal cancer, liver cancer

Interventions

Treatment group:Intraoperative fluid therapy: choose Ringer's solution for crystals and 10% human albumin or hydroxyethyl starch solutionfor colloids
Contronl group:Intraoperative fluid therapy: Ringer's fluid was selected for crystallography, and no colloidal fluid was injected

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years old, ASA grade ?, grade ?; 2. scheduled to undergo major abdominal surgery, the types of surgery include radical resection of esophageal cancer, radical resection of gastric cancer, radical resection of colorectal cancer, radical resection of liver cancer; 3. Normal or mildly impaired cardiopulmonary function before surgery; 4. The patient or their family member agrees and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing emergency surgery; 2. Patients with severe preoperative cardiopulmonary insufficiency, hepatic or renal dysfunction (bilirubin > 2 times the upper limit of normal, transaminases > 3 times the upper limit of normal, creatinine > 117 µmol/L, creatinine clearance rate 3 seconds), fever, infection, etc.; 3. Patients who have already received fluid management interventions before surgery; 4. Patients participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Albumin;Globulin;

Secondary

MeasureTime frame
Stroke volume variation;

Countries

China

Contacts

Public ContactHaijian Shen

Chongqing University Cancer Hospital

shenhj17@126.com+86 137 8189 2015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026